David Apelian

David Apelian

Chief Executive Officer at EIGER BIOPHARMACEUTICALS
61 year
Health Technology
Consumer Services

Profile

Dr. David Apelian is a Chief Executive Officer at Theolytics Ltd. and a Chief Executive Officer & Director at Eiger BioPharmaceuticals, Inc. He is on the Board of Directors at Eiger BioPharmaceuticals, Inc. Dr. Apelian was previously employed as a Chief Executive Officer & Director by BlueSphere Bio, Inc., a Chief Medical Officer & Executive Vice President by Achillion Pharmaceuticals, Inc., a Chief Medical Officer, SVP-Research & Development by GlobeImmune, Inc., a Clinical Director-Infectious Diseases Group by Bristol Myers Squibb Co., a Clinical Director-Hepatology Department by Schering-Plough Corp., and a Vice President by Wyeth Pharmaceuticals LLC.
He received his undergraduate degree from Rutgers State University of New Jersey, an MBA from Quinnipiac University, a doctorate degree from the University of Medicine & Dentistry of New Jersey and a doctorate degree from Rutgers State University of New Jersey.

David Apelian active positions

CompaniesPositionStart
EIGER BIOPHARMACEUTICALS Chief Executive Officer 15/12/2022
Chief Executive Officer 17/12/2024

Former positions of David Apelian

CompaniesPositionEnd
Chief Executive Officer 04/10/2022
ACHILLION PHARMACEUTICALS, INC. Chief Tech/Sci/R&D Officer 28/12/2017
GLOBEIMMUNE, INC. Chief Tech/Sci/R&D Officer 01/01/2013
BRISTOL-MYERS SQUIBB COMPANY Chief Tech/Sci/R&D Officer -
Chief Tech/Sci/R&D Officer -
See the detail of David Apelian's experience

Training of David Apelian

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

72

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies11

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!